Jubilant Pharmova’s arm receives USFDA’s approval for Technetium Mertiatide Injection

01 Feb 2023 Evaluate

Jubilant Pharmova’s wholly owned subsidiary--Jubilant Draximage Inc has received approval from the United States Food and Drug Administration (USFDA) with regards to the company’s new drug application (NDA) submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Kit for the Preparation of Technetium (Tc 99m) Mertiatide Injection.

The Tc 99m Mertiatide Injection is used in the diagnosis of congenital and acquired renal abnormalities, renal failure, urinary tract obstruction, and calculi in adults and pediatric patients aged 30 days and older. The product enables providing renal function, split function, renal angiograms, and renogram curves for whole kidney and renal cortex. This approval is effective from January 30, 2023.

Jubilant Pharmova (formerly Jubilant Life Sciences) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses.
 

Jubilant Pharmova Share Price

1054.10 -20.20 (-1.88%)
29-Dec-2025 14:20 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.60
Dr. Reddys Lab 1266.00
Cipla 1495.00
Zydus Lifesciences 905.65
Lupin 2082.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×